These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 30845885

  • 1. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M, Husain S, Famure O, Li Y, Kim SJ.
    Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
    [Abstract] [Full Text] [Related]

  • 2. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [Abstract] [Full Text] [Related]

  • 3. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 4. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM, Burkett P, Divo M, Keller S, Rosas IO, Trindade A, Mody GN, Singh SK, El-Chemaly S, Camp PC, Goldberg HJ, Mallidi HR.
    Ann Thorac Surg; 2018 Feb 15; 105(2):441-447. PubMed ID: 29223419
    [Abstract] [Full Text] [Related]

  • 5. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 15; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 6. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B, Riella LV, Dierickx D.
    Am J Kidney Dis; 2021 Aug 15; 78(2):272-281. PubMed ID: 33774079
    [Abstract] [Full Text] [Related]

  • 7. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun 15; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 8. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Studies of Pediatric Liver Transplantation Research Group.
    Liver Transpl; 2013 Jul 15; 19(7):730-40. PubMed ID: 23696264
    [Abstract] [Full Text] [Related]

  • 9. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep 15; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC.
    Transplantation; 2004 Jul 27; 78(2):205-10. PubMed ID: 15280679
    [Abstract] [Full Text] [Related]

  • 11. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
    Kasiske BL, Kukla A, Thomas D, Wood Ives J, Snyder JJ, Qiu Y, Peng Y, Dharnidharka VR, Israni AK.
    Am J Kidney Dis; 2011 Dec 27; 58(6):971-80. PubMed ID: 21930332
    [Abstract] [Full Text] [Related]

  • 12. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
    OʼRegan JA, Prendeville S, McCaughan JA, Traynor C, OʼBrien FJ, Ward FL, OʼDonovan D, Kennedy C, Berzan E, Kinsella S, Williams Y, OʼKelly P, Deady S, Comber H, Leader M, Conlon PJ.
    Transplantation; 2017 Mar 27; 101(3):657-663. PubMed ID: 27214265
    [Abstract] [Full Text] [Related]

  • 13. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 14. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM, Adams W, Grim SA, Clark NM, Edwards L, Layden JE.
    J Cyst Fibros; 2017 Nov 15; 16(6):727-734. PubMed ID: 28456611
    [Abstract] [Full Text] [Related]

  • 15. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 15; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 16. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG, Tan MYQ, Quak SH, Aw MM.
    Transpl Infect Dis; 2018 Feb 15; 20(1):. PubMed ID: 29071779
    [Abstract] [Full Text] [Related]

  • 17. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
    Hyun H, Park E, Cho M, Min SI, Ha J, Kang HJ, Shin HY, Ha IS, Cheong HI, Ahn YH, Kang HG.
    J Korean Med Sci; 2019 Aug 05; 34(30):e203. PubMed ID: 31373185
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
    Shahinian VB, Muirhead N, Jevnikar AM, Leckie SH, Khakhar AK, Luke PP, Rizkalla KS, Hollomby DJ, House AA.
    Transplantation; 2003 Mar 27; 75(6):851-6. PubMed ID: 12660514
    [Abstract] [Full Text] [Related]

  • 19. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S, Varnous S, Deback C, Golmard JL, Leblond V.
    Am J Transplant; 2014 Apr 27; 14(4):857-66. PubMed ID: 24666832
    [Abstract] [Full Text] [Related]

  • 20. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.